Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
about
Idiotype vaccination for Non-Hodgkin lymphomaIdiotype vaccination for Non-Hodgkin lymphomaUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaRadioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation OncologistsIbritumomab tiuxetan for non-Hodgkin's lymphoma.Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.Antibody-based therapeutics in oncology.Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters.The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative MedicineA review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma.Review of clinical radioimmunotherapy.Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.Advances in the treatment for haematological malignancies.Yttrium 90 ibritumomab tiuxetan in lymphoma.Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphomaExpression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.Current management of follicular lymphomas.Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.New insights into the mechanisms of action of radioimmunotherapy in lymphoma.Treatment of follicular lymphoma: current status.The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.Immunotherapy for HIV-associated non-Hodgkin's lymphoma.Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Radioimmunotherapy in mantle cell lymphoma.Radioimmunotherapy for B-cell non-hodgkin lymphomas.The role of monoclonal antibodies in the treatment of lymphomas.
P2860
Q24186272-15BEB2EC-10AF-4575-9E39-6511F6F2EA4FQ24235281-52D7E5CA-73E3-4D0D-A585-26F33245357BQ24633710-E3AD377F-CC10-4649-B601-FA83A98F5B09Q29030891-CD8FDD0A-E040-42D3-9AB8-6F2F1570845CQ33371489-FA3F380A-9060-492F-8FAE-EC51D52EFEE8Q33376503-F1C45BE1-015D-4277-BA7A-A1BB04187694Q33402885-974661F4-09BD-4EEF-A016-29A678CB6F32Q33409137-E62715E4-F67E-4900-A41E-41E35A0F5FCAQ33605615-6090B990-38CE-48A7-AF2C-590346D2C6A4Q34216815-7DEBF392-0970-4799-BD4B-F7BA79B5FB5EQ34335207-2F4C4FAE-2D28-4064-ACC1-BC2F58581E8AQ34567445-AC2ADB55-949E-4259-8A2B-7C1F03626D1AQ34631795-4DDA5247-E1F3-45DB-807F-1B81D616916FQ34969165-22EE20A1-59DE-4CC2-830B-2D5B210DFC7AQ35070445-22659FDF-A2AD-47AB-A22C-D65F1701603EQ35111994-1CB4AE0B-9E06-478C-9EEF-B717A3F536A8Q35115650-A377D9CD-7E1C-4A02-A07C-2DB73BCF0DB8Q35808435-6CEB9DF0-C38C-473F-A22F-6B2CE22DC14AQ35928383-6F4C2EDB-BAF2-4AE2-B377-EAFEF7CCD399Q36150468-BF81AB69-8FC3-4E6F-88EB-86891F4ADDD3Q36407480-2C72CC53-766C-4311-9060-29192962AEB0Q36426877-245888AD-35E3-490E-B67C-3C362427073BQ36429723-769868CE-14FA-44FF-A3F2-39114831BC46Q36535485-4C860ED8-47CC-48B9-955D-B91D3090719AQ36614459-63436F8D-3A95-4697-8FDB-F222FCD1661FQ36615307-2C1A26CA-38D9-4BCF-8476-5453EE70CFFBQ36639053-BD1CE1B3-8BBC-4D15-AE3B-0A7EFD3D28AEQ36684500-29266AA4-2E41-47F1-9EC2-53F64BC5C5F6Q36950052-29C3079A-DF6A-4BBA-B8B8-B9C6FFB03AD5Q37045536-4652A363-2F9E-4509-93F4-A12F6D394E36Q37222783-3828B54B-4B0F-420A-8592-D6402B79C791Q37280915-982B71C9-184F-49A3-96FA-0A076615B645Q37390535-DD0D6B0B-CE8E-455F-A90D-1E45FEF0CCC5Q37567836-2D53F761-A1C3-4B66-BFAF-CC7BD7685891Q37586857-E1F0CCA9-19AB-4EDF-8F26-1424575783E0Q37752447-F80526F2-46F6-4772-8660-46B1B4C13B0EQ37877728-0BEF5A36-D669-4CAC-9547-71FD9A74A7B4Q38017790-F1E4A9B5-F408-4645-A9B6-8065485DF8EAQ38019790-EFC9C24C-49F6-465E-9A5B-728238186042Q38069595-95DFCE17-FA28-45FA-85E7-8D50F479E8A6
P2860
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Ibritumomab tiuxetan radioimmu ...... a phase II multicenter trial.
@ast
Ibritumomab tiuxetan radioimmu ...... a phase II multicenter trial.
@en
type
label
Ibritumomab tiuxetan radioimmu ...... a phase II multicenter trial.
@ast
Ibritumomab tiuxetan radioimmu ...... a phase II multicenter trial.
@en
prefLabel
Ibritumomab tiuxetan radioimmu ...... a phase II multicenter trial.
@ast
Ibritumomab tiuxetan radioimmu ...... a phase II multicenter trial.
@en
P2093
P921
P1433
P1476
Ibritumomab tiuxetan radioimmu ...... : a phase II multicenter trial
@en
P2093
Antonio J Grillo-López
Christine A White
Gregory A Wiseman
James L Murray
Mansoor Saleh
Pratik S Multani
Roberta S Allen
Russell J Schilder
Stewart Spies
Thomas E Witzig
P304
P356
10.1182/BLOOD.V99.12.4336
P407
P577
2002-06-01T00:00:00Z